Eli Lilly’s weight-loss medication Foundayo continues making headlines following its FDA approval earlier this month on April 1. Fresh clinical trial results are now providing additional momentum for the pharmaceutical giant.
Recently published data from a comprehensive late-stage clinical trial involving over 2,700 participants revealed that individuals receiving Foundayo experienced a 16% decreased risk of major adverse cardiovascular events—including heart attack, stroke, and death from cardiovascular causes—when compared with patients receiving insulin glargine, a conventional long-acting insulin therapy prescribed for both type 1 and type 2 diabetes management.
Perhaps more striking, the medication achieved a 57% reduction in mortality from all causes—a statistic that immediately captured the attention of investors and medical professionals alike.
The clinical investigation specifically targeted adult participants diagnosed with type 2 diabetes who were also dealing with obesity and faced elevated cardiovascular risk profiles. Beyond cardiovascular outcomes, Foundayo delivered improvements in A1C levels—a critical marker that reflects average blood glucose concentrations over a multi-month period—while simultaneously reducing body weight after 52 weeks of treatment. In contrast, participants assigned to the insulin glargine control group experienced weight gain during the same timeframe.
Lilly announced that the trial successfully achieved its primary endpoints, paving the way for the company to pursue FDA approval of Foundayo for type 2 diabetes treatment. The pharmaceutical manufacturer intends to utilize a Commissioner’s National Priority Review Voucher to accelerate the regulatory review timeline. The regulatory submission is anticipated before the close of the second quarter in 2026.
A significant challenge facing Foundayo has been the FDA’s requirement for additional data concerning potential hepatic injury. The most recent trial incorporated a comprehensive liver safety analysis, which revealed no evidence of liver-related safety issues—findings that align with previous research studies.
RBC Capital Markets analyst Trung Huynh indicated that these results should effectively address concerns that Foundayo presents distinctive liver safety risks compared to rival therapies such as Novo Nordisk’s oral formulation of Wegovy, which launched commercially in January.
This represents an important milestone for Eli Lilly. With Novo Nordisk having secured first-mover advantage in the oral obesity medication market, any persistent safety uncertainties surrounding Foundayo could have significantly hampered its market prospects.
The cardiovascular findings complement an already broadening therapeutic profile for the medication. Previous clinical investigations have identified potential therapeutic effects across diverse conditions including hypertension and alcohol use disorder.
Industry analysts project that Foundayo could generate peak annual revenues of $36 billion based on current market assessments.
LLY shares advanced 0.86% on the session when these trial results were disclosed. The stock currently holds a Strong Buy consensus rating from 19 Wall Street analysts—comprising 16 Buy recommendations, 2 Hold ratings, and 1 Sell rating—with an average price objective of $1,247.38, suggesting approximately 31.5% upside potential from present trading levels.
The company’s regulatory filing for the diabetes indication is scheduled for submission by the conclusion of Q2 2026.
The post Eli Lilly (LLY) Stock Climbs on Foundayo Trial Results Showing 57% Reduction in Death Risk appeared first on Blockonomi.
